Temozolomide in children with progressive low-grade glioma

Neuro-Oncology

Volumn 9, Issue 2, 2007, Pages 161-168

  Gururangan, Sridharan ^a   Fisher, Michael J ^b   Allen, Jeffrey C ^c   Herndon II, James E ^a   Quinn, Jennifer A ^a   Reardon, David A ^a   Vredenburgh, James J ^a   Desjardins, Annick ^a   Phillips, Peter C ^b   Watral, Melody A ^a   Krauser, Jeanne M ^a   Friedman, Allan H ^a   Friedman, Henry S ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Low grade glioma; Phase II trial; Responses; Temozolomide

Indexed keywords

CARBOPLATIN; ESTRAMUSTINE; ETOPOSIDE; IRINOTECAN; LOMUSTINE; PROCARBAZINE; TEMOZOLOMIDE; TIOGUANINE; VINBLASTINE; VINCRISTINE;

ADOLESCENT; ADULT; ARTICLE; ASTROCYTOMA; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG FATALITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GLIOMA; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OPTIC NERVE GLIOMA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR BLEEDING;

ADOLESCENT; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; DACARBAZINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLIOMA; HUMANS; MALE; SURVIVAL ANALYSIS; SURVIVORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 34147192979     PISSN: 15228517     EISSN: None     Source Type: Journal    
DOI: 10.1215/15228517-2006-030     Document Type: Article

References (23)

1. Allen, J.C., Judkins, A.R., Rosenblum, M.K., and Biegel, J.A. (2006) Atypical teratoid/rhabdoid tumor arising from an optic pathway ganglioglioma: Case study. Neuro-Oncology 8, 79-82.
2. 6-benzylguanine, and resistance to clinical alkylators in pediatric primary brain tumor cell lines. Clin. Cancer Res. 11, 2747-2755.
3. Brada, M., Judson, I., Beale, P., Moore, S., Reidenberg, P., Statkevich, P., Dugan, M., Batra, V., and Cutler, D. (1999) Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies. Br. J. Cancer 81, 1022-1030.
4. Brada, M., Viviers, L., Abson, C., Hines, F., Britton, J., Ashley, S., Sardell, S., Traish, D., Gonsalves, A., Wilkins, P., and Westbury, C. (2003) Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas. Ann. Oncol. 14, 1715-1721.
5. De Vita, S., De Matteis, S., Laurenti, L., Chiusolo, P., Reddiconto, G., Fiorini, A., Leone, G., and Sica, S. (2005) Secondary Ph+ acute lymphoblastic leukemia after temozolomide. Ann. Hematol. 84, 760-762.
6. Duffner, P.K., and Cohen, M.E. (1991) The long-term effects of central nervous system therapy on children with brain tumors. Neurol. Clin. 9, 479-495.
7. Friedman, H.S., Kerby, T., and Calvert, H. (2000) Temozolomide and treatment of malignant glioma. Clin. Cancer Res. 6, 2585-2597.
8. 6-Benzylguanine- mediated enhancement of chemotherapy. Mol. Cancer Ther. 1, 943-948.
9. Gerson, S.L. (2002) Clinical relevance of MGMT in the treatment of cancer. J. Clin. Oncol. 20, 2388-2399.
10. Grill, J., Couanet, D., Cappelli, C., Habrand, J.L., Rodriguez, D., Sainte-Rose, C., and Kalifa, C. (1999) Radiation-induced cerebral vasculopathy in children with neurofibromatosis and optic pathway glioma. Ann. Neurol. 45, 393-396.
11. Gururangan, S., Cavazos, C.M., Ashley, D., Herndon, J.E., II, Bruggers, C.S., Moghrabi, A., Scarcella, D.L., Watral, M., Tourt-Uhlig, S., Reardon, D., and Friedman, H.S. (2002) Phase II study of carboplatin in children with progressive low-grade gliomas. J. Clin. Oncol. 20, 2951-2958.
12. Hoang-Xuan, K., Capelle, L., Kujas, M., Taillibert, S., Duffau, H., Lejeune, J., Polivka, M., Criniere, E., Marie, Y., Mokhtari, K., Carpentier, A.F., Laigle, F., Simon, J.M., Cornu, P., Broet, P., Sanson, M., and Delattre, J.Y. (2004) Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J. Clin. Oncol. 22, 3133-3138.
13. Kuo, D.J., Weiner, H.L., Wisoff, J., Miller, D.C., Knopp, E.A., and Finlay, J.L. (2003) Temozolomide is active in childhood, progressive, unresectable, low-grade gliomas. J. Pediatr. Hematol. Oncol. 25, 372-378.
14. Nicholson, H.S., Krailo, M., Ames, M.M., Seibel, N.L., Reid, J.M., Liu-Mares, W., Vezina, L.G., Ettinger, A.G., and Reaman, G.H. (1998) Phase I study of temozolomide in children and adolescents with recurrent solid tumors: A report from the Children's Cancer Group. J. Clin. Oncol. 16, 3037-3043.
15. Ostermann, S., Csajka, C., Buclin, T., Leyvraz, S., Lejeune, F., Decosterd, L.A., and Stupp, R. (2004) Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. Clin. Cancer Res. 10, 3728-3736.
16. Pace, A., Vidiri, A., Galie, E., Carosi, M., Telera, S., Cianciulli, A.M., Canalini, P., Giannarelli, D., Jandolo, B., and Carapella, C.M. (2003) Temozolomide chemotherapy for progressive low-grade glioma: Clinical benefits and radiological response. Ann. Oncol. 14, 1722-1726.
17. Packer, R.J., Ater, J., Allen, J., Phillips, P., Geyer, R., Nicholson, H.S., Jakacki, R., Kurczynski, E., Needle, M., Finlay, J., Reaman, G., and Boyett, J.M. (1997) Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. J. Neurosurg. 86, 747-754.
18. Perilongo, G. (2005) Considerations on the role of chemotherapy and modern radiotherapy in the treatment of childhood low grade glioma. J. Neurooncol. 75, 301-307.
19. Prados, M.D., Edwards, M.S., Rabbitt, J., Lamborn, K., Davis, R.L., and Levin, V.A. (1997) Treatment of pediatric low-grade gliomas with a nitrosourea-based multiagent chemotherapy regimen. J. Neurooncol. 32, 235-241.
20. Quinn, J.A., Reardon, D.A., Friedman, A.H., Rich, J.N., Sampson, J.H., Provenzale, J.M., Mclendon, R.E., Gururangan, S., Bigner, D.D., Herndon, J.E., II, Avgeropoulos, N., Finlay, J., Tourt-Uhlig, S., Affronti, M.L., Evans, B., Stafford-Fox, V., Zaknoen, S., and Friedman, H.S. (2003) Phase II trial of temozolomide in patients with progressive low-grade glioma. J. Clin. Oncol. 21, 646-651.
21. 6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br. J. Cancer 88, 1004-1011.
22. 6-benzylguanine and temozolomide administered daily for 5 days to pediatric patients with solid tumors. J. Clin. Oncol. 23, 7646-7653.
23. Watson, G.A., Kadota, R.P., and Wisoff, J.H. (2001) Multidisciplinary management of pediatric low-grade gliomas. Semin. Radiat. Oncol. 11, 152-162.